Can transcatheter edge-to-edge repair change the paradigm in severe acute mitral regurgitation? A mechanism-based approach ¿La reparación percutánea de borde a borde puede cambiar el paradigma en la ...

JenaValve Technology has received premarket approval from the FDA for its Trilogy THV System.  The system is now the first transcatheter device in the U.S. with a dedicated indication for patients ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...

With its FDA approval, JenaValve intends to commence launch activity for the Trilogy System immediately with participating ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...